Heron Therapeutics (HRTX) Common Equity (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Common Equity came in at $9.1 million in Q1 2026, up 132.11% YoY from $3.9 million in Q1 2025, and down 36.25% on a QoQ basis from $14.3 million in Q4 2025.
Heron Therapeutics (HRTX) Common Equity (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Common Equity data on file, last reported at $9.1 million in Q1 2026.
- Quarterly Common Equity rose 132.11% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 132.11% YoY) and the FY2025 annual result came in at $14.3 million, up 142.59% from the prior year.
- Common Equity fell to $9.1 million in Q1 2026, from $14.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $24.0 million in Q1 2022 to a low of -$40.0 million in Q3 2024.
- A 5-year average of -$13.9 million and a median of -$27.3 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity tumbled 350.32% — and 2025, when it jumped 142.59%.
- Tracing HRTX's Common Equity over 5 years: stood at $13.6 million in 2022, then sank by 350.32% to -$34.0 million in 2023, then increased by 0.95% to -$33.7 million in 2024, then soared by 142.59% to $14.3 million in 2025, then tumbled by 36.25% to $9.1 million in 2026.
- The last three Common Equity figures came in at $9.1 million (Q1 2026), $14.3 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | 6.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.91 Mn |
| Mar 31, 2026 | 9.14 Mn |
| Dec 31, 2025 | 14.33 Mn |
| Sep 30, 2025 | 14.89 Mn |
| Jun 30, 2025 | -27.26 Mn |
| Mar 31, 2025 | -28.45 Mn |
| Dec 31, 2024 | -33.65 Mn |
| Sep 30, 2024 | -40.01 Mn |
| Jun 30, 2024 | -37.94 Mn |
| Mar 31, 2024 | -33.77 Mn |
| Dec 31, 2023 | -33.97 Mn |
| Sep 30, 2023 | -27.79 Mn |
| Jun 30, 2023 | -39.28 Mn |
| Mar 31, 2023 | -11.43 Mn |
| Dec 31, 2022 | 13.57 Mn |
| Sep 30, 2022 | 22.45 Mn |
| Jun 30, 2022 | -21.74 Mn |
| Mar 31, 2022 | 23.96 Mn |
| Dec 31, 2021 | 77.57 Mn |
| Sep 30, 2021 | 118.84 Mn |